M. D. Vesely, M. H. Kershaw, R. D. Schreiber, and M. J. Smyth, Natural innate and adaptive immunity to cancer, Annu Rev Immunol, vol.29, pp.235-271, 2011.

S. A. Rosenberg, J. C. Yang, and N. P. Restifo, Cancer immunotherapy: moving beyond current vaccines, Nat Med, vol.10, pp.909-915, 2004.

D. J. Schwartzentruber, D. H. Lawson, J. M. Richards, R. M. Conry, and D. M. Miller, ) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma, N Engl J Med, vol.364, pp.2119-2127, 2011.

M. S. Bijker, S. J. Van-den-eeden, K. L. Franken, C. J. Melief, and R. Offringa, CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity, J Immunol, vol.179, pp.5033-5040, 2007.

R. E. Toes, R. Offringa, R. J. Blom, C. J. Melief, and W. M. Kast, Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction, Proc Natl Acad Sci U S A, vol.93, pp.7855-7860, 1996.

K. L. Knutson and M. L. Disis, Tumor antigen-specific T helper cells in cancer immunity and immunotherapy, Cancer Immunol Immunother, vol.54, pp.721-728, 2005.

R. Kennedy and E. Celis, Multiple roles for CD4+ T cells in anti-tumor immune responses, Immunol Rev, vol.222, pp.129-144, 2008.

S. R. Bennett, F. R. Carbone, F. Karamalis, R. A. Flavell, and J. F. Miller, Help for cytotoxic-T-cell responses is mediated by CD40 signalling, Nature, vol.393, pp.478-480, 1998.

C. M. Smith, N. S. Wilson, J. Waithman, J. A. Villadangos, and F. R. Carbone, , 2004.

C. Cognate, +) T cell licensing of dendritic cells in CD8(+) T cell immunity, Nat Immunol, vol.5, pp.1143-1148

Z. Qin and T. Blankenstein, CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells, Immunity, vol.12, pp.677-686, 2000.

R. Bos and L. A. Sherman, CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes, Cancer Res, vol.70, pp.8368-8377, 2010.

M. Tosolini, A. Kirilovsky, B. Mlecnik, T. Fredriksen, and S. Mauger, Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer, Cancer Res, vol.71, pp.1263-1271, 2011.

P. F. Robbins, M. El-gamil, Y. F. Li, G. Zeng, and M. Dudley, Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumorinfiltrating lymphocytes from a patient with melanoma, J Immunol, vol.169, pp.6036-6047, 2002.

K. M. Friedman, P. A. Prieto, L. E. Devillier, C. A. Gross, and J. C. Yang, Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes, J Immunother, 2012.

N. N. Hunder, H. Wallen, J. Cao, D. W. Hendricks, and J. Z. Reilly, Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1, N Engl J Med, vol.358, pp.2698-2703, 2008.

C. Fayolle, E. Deriaud, and C. Leclerc, In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help, J Immunol, vol.147, pp.4069-4073, 1991.

F. M. Speetjens, P. J. Kuppen, M. J. Welters, F. Essahsah, . Voet-van-den et al., Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer, Clin Cancer Res, vol.15, pp.1086-1095, 2009.

G. G. Kenter, M. J. Welters, A. R. Valentijn, M. J. Lowik, and D. M. Berends-van-der-meer, Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia, N Engl J Med, vol.361, pp.1838-1847, 2009.

M. J. Welters, G. G. Kenter, S. J. Piersma, A. P. Vloon, and M. J. Lowik, Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine, Clin Cancer Res, vol.14, pp.178-187, 2008.

J. M. Chauvin, P. Larrieu, G. Sarrabayrouse, A. Prevost-blondel, and R. Lengagne, HLA Anchor Optimization of the Melan-A-HLA-A2 Epitope within a Long Peptide Is Required for Efficient Cross-Priming of Human Tumor-Reactive T Cells, J Immunol, vol.188, pp.2102-2110, 2012.

Y. Godet, A. Moreau-aubry, Y. Guilloux, V. Vignard, and A. Khammari, MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency, J Exp Med, vol.205, pp.2673-2682, 2008.

Y. Godet, J. Desfrancois, V. Vignard, D. Schadendorf, and A. Khammari, Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy, Eur J Immunol, vol.40, pp.1786-1794, 2010.

A. Rogel, V. Vignard, M. Bobinet, N. Labarriere, and F. Lang, A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination, Cancer Immunol Immunother, vol.60, pp.327-337, 2011.

X. F. Wang, J. Kerzerho, O. Adotevi, H. Nuyttens, and C. Badoual, Comprehensive analysis of HLA-DR-and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients, J Immunol, vol.181, pp.431-439, 2008.

N. Gervois, N. Labarriere, L. Guiner, S. Pandolfino, M. C. Fonteneau et al., High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells, Clin Cancer Res, vol.6, pp.1459-1467, 2000.

F. Davodeau, M. Difilippantonio, E. Roldan, M. Malissen, and J. L. Casanova, The tight interallelic positional coincidence that distinguishes T-cell receptor Jalpha usage does not result from homologous chromosomal pairing during ValphaJalpha rearrangement, EMBO J, vol.20, pp.4717-4729, 2001.

B. Arden, S. P. Clark, D. Kabelitz, and T. W. Mak, Human T-cell receptor variable gene segment families, Immunogenetics, vol.42, pp.455-500, 1995.

K. L. Knutson, K. Schiffman, and M. L. Disis, Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients, J Clin Invest, vol.107, pp.477-484, 2001.

C. J. Melief and S. H. Van-der-burg, Immunotherapy of established (pre)-malignant disease by synthetic long peptide vaccines, Nat Rev Cancer, vol.8, pp.351-360, 2008.

S. Gnjatic, D. Atanackovic, E. Jager, M. Matsuo, and A. Selvakumar, Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses, Proc Natl Acad Sci U S A, vol.100, pp.8862-8867, 2003.

M. Mandic, F. Castelli, B. Janjic, C. Almunia, and P. Andrade, One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma, J Immunol, vol.174, pp.1751-1759, 2005.

H. M. Zarour, B. Maillere, V. Brusic, K. Coval, and E. Williams, NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1-and Th2-type tumor-reactive CD4+ T cells, Cancer Res, vol.62, pp.213-218, 2002.

D. Mumberg, P. A. Monach, S. Wanderling, M. Philip, and A. Y. Toledano, CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma, Proc Natl Acad Sci U S A, vol.96, pp.8633-8638, 1999.

J. A. Kyte, S. Trachsel, B. Risberg, P. Thor-straten, and K. Lislerud, Unconventional cytokine profiles and development of T cell memory in longterm survivors after cancer vaccination, Cancer Immunol Immunother, vol.58, pp.1609-1626, 2009.

J. Fourcade, Z. Sun, P. Kudela, B. Janjic, and J. M. Kirkwood, Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire, J Immunol, vol.184, pp.6709-6718, 2010.

V. Francois, S. Ottaviani, N. Renkvist, J. Stockis, and G. Schuler, The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells, Cancer Res, vol.69, pp.4335-4345, 2009.

H. Y. Wang, D. A. Lee, G. Peng, Z. Guo, and Y. Li, Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy, Immunity, vol.20, pp.107-118, 2004.

E. S. Schultz, B. Lethe, C. L. Cambiaso, J. Van-snick, and P. Chaux, A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes, Cancer Res, vol.60, pp.6272-6275, 2000.